leveljump

LevelJump Board of Directors Update

 LevelJump Healthcare Corp. (TSXV: JUMP) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, announces a change in the board of directors.

Effective May 3, 2021, Mr. Michael Newman has resigned from the board of directors of the Company.

"We thank Mr. Newman for his time on the board during our going public process." Said Mitch Geisler, CEO. "Moving forward the board will be looking to replace the vacant seat by identifying a person with expertise in our field who can help the Company implement our long term growth plans."

About Leveljump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) is building a national medical diagnostic imaging company and brand, primarily by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP plans to expand through the acquisition of independent healthcare facilities focused on diagnostic imaging as well as acquiring new disruptive imaging technologies.

ON BEHALF OF THE BOARD OF DIRECTORS OF

LevelJump Healthcare Corp.

Mitchell Geisler, Chief Executive Officer
info@leveljumphealthcare.com
(833) 840-2020

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82712

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), a standard immunotherapy, is statistically significantly superior to results observed from treatment with either agent individually or the control group. This second phase of the Study has documented that, in a cohort of six animals, 66 of treated triple negative breast cancer, the most aggressive and therapy resistant form, mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, resulting in a flattening of the tumor growth curves, as shown in the below graph. The generation of hyperthermia involved exposing tumors previously injected intratumorally with Sona's gold nanorods and IL-2 to a single dose of near infrared light.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Nextech3D.ai Announces Date For Financial Results and Webcast For Fourth Quarter & Full Year 2023

Nextech3D.ai Announces Date For Financial Results and Webcast For Fourth Quarter & Full Year 2023

-

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a patented 2D-3D Generative AI-Powered 3D model supplier (Patent #11,948,248) for Amazon, Miele, P&G, Kohls, Wesfarmers Group "Bunnings" (Australia's largest listed company) and other major e-commerce retailers will release its audited full year and fourth quarter 2023 financial results after markets close on Monday, April 29, 2024

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Nanalysis Announces Full Year 2023 Conference Call

Hosting Call at 5:00 pm ET on Thursday , April 25th

European Q&A Session on Friday April 26 th at 8:30am ET

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Nanalysis Scientific Corp. Announces Director Resignation

Nanalysis Scientific Corp. (" Nanalysis " or the " Company ", (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) announces that Kham Lin has resigned as a director of the Company effective April 9, 2024 and the Board of Directors has accepted his resignation. The Company would like to thank Mr. Lin for his contributions throughout his tenure as director of the Company.

Nanalysis Scientific Corp. Logo (CNW Group/Nanalysis Scientific Corp.)

About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1)

Nanalysis Scientific Corp. operates two primary businesses: Scientific Equipment and Security Services. Within its Scientific Equipment business is what the Company terms "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60â„¢ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The Company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. In 2020, the Company announced the launch of its 100MHz device, the most powerful and most advanced compact NMR device ever brought to market.

The Company's devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners. With its partners, the Company provides scientific equipment sales and maintenance services globally.

In 2022, through its subsidiary KPrime, the Company was awarded a five-year, $160 million contract with the Government of Canada to provide maintenance services for passenger screening equipment in Canadian airports. This has resulted in the expansion of the Company's Security Services business. The Company is providing airport security equipment maintenance services for the Government of Canada in each province and territory of Canada . In addition, the Company provides commercial security equipment installation and maintenance services to a variety of customers in North America.

Notice regarding Forward Looking Statements and Legal Disclaimer

All statements included herein, other than statements of historical fact, may be forward-looking information and such information involves various risks and uncertainties. Forward-looking information is often, but not always, identified by the use of words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-director-resignation-302113222.html

SOURCE Nanalysis Scientific Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2024/10/c1267.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
ARway.ai The Spatial Computing Platform Shows 200% Developer Growth, Signs Multiple New Deals for Its Augmented Reality Navigation Platform in Middle East & Spain

ARway.ai The Spatial Computing Platform Shows 200% Developer Growth, Signs Multiple New Deals for Its Augmented Reality Navigation Platform in Middle East & Spain

In Addition the Company Has Signed Several New University Student Plans

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce two new SaaS developer deals with leading companies in the Saudi Arabia and Spain. These partnerships underscore ARway.ai's commitment to enhancing spatial computing across various sectors and use cases, reaffirming its position as a leader in AR technology integration

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development

Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.

The Company is receiving advisory services and up to $24,894 in funding from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") IP Assist program to support the development of an intellectual property strategy for Sona's proprietary gold nanorods for novel targeted drug delivery concepts with a view to securing new patents.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
{{ sections }}

Latest Press Releases

Related News

×